Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence

Alcoholism: Clinical and Experimental Research

Volumn 35, Issue 11, 2011, Pages 2030-2038

  Schacht, Joseph P ^a   Randall, Patrick K ^a   Waid, L R ^a   Baros, Alicia M ^a   Latham, Patricia K ^a   Wright, Tara M ^a,b   Myrick, Hugh ^a,b   Anton, Raymond F ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

aminobutyric acid; Alcoholism; Anticonvulsant; Neurocognitive; Withdrawal

Indexed keywords

4 AMINOBUTYRIC ACID; FLUMAZENIL; GABAPENTIN; GLUTAMIC ACID; PLACEBO;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; COGNITION; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HUMAN; INHIBITION (PSYCHOLOGY); MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; AMINES; COGNITION; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; FLUMAZENIL; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 80055120788     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2011.01554.x     Document Type: Article

References (68)

1. Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM, Stewart SH, Waid R, Malcolm R (2009) Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol 29:334-342.
2. Bates ME, Bowden SC, Barry D (2002) Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol 10:193-212.
3. Becker HC, Hale RL (1993) Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal "kindling". Alcohol Clin Exp Res 17:94-98.
4. Behar KL, Rothman DL, Petersen KF, Hooten M, Delaney R, Petroff OA, Shulman GI, Navarro V, Petrakis IL, Charney DS, Krystal JH (1999) Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 156:952-954.
5. Biggio F, Gorini G, Caria S, Murru L, Sanna E, Follesa P (2007) Flumazenil selectively prevents the increase in alpha(4)-subunit gene expression and an associated change in GABA(A) receptor function induced by ethanol withdrawal. J Neurochem 102:657-666.
6. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M (1999) Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 32:107-109.
7. Buck KK, Atkinson TM, Ryan JP (2008) Evidence of practice effects in variants of the Trail Making Test during serial assessment. J Clin Exp Neuropsychol 30:312-318.
8. Cagetti E, Liang J, Spigelman I, Olsen RW (2003) Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol 63:53-64.
9. Charney DA, Zikos E, Gill KJ (2010) Early recovery from alcohol dependence: factors that promote or impede abstinence. J Subst Abuse Treat 38:42-50.
10. Cohen J (1992) A power primer. Psychol Bull 112:155-159.
11. Conners CK (2000) Conners' Continuous Performance Test-II. Multi-Health Systems, Toronto.
12. Cordovil De Sousa Uva M, Luminet O, Cortesi M, Constant E, Derely M, De Timary P (2010) Distinct effects of protracted withdrawal on affect, craving, selective attention and executive functions among alcohol-dependent patients. Alcohol Alcohol 45:241-246.
13. Criswell HE, Ming Z, Kelm MK, Breese GR (2008) Brain regional differences in the effect of ethanol on GABA release from presynaptic terminals. J Pharmacol Exp Ther 326:596-603.
14. Davidson DJ, Zacks RT, Williams CC (2003) Stroop interference, practice, and aging. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 10:85-98.
15. Duka T, Townshend JM, Collier K, Stephens DN (2003) Impairment in cognitive functions after multiple detoxifications in alcoholic inpatients. Alcohol Clin Exp Res 27:1563-1572.
16. Feldstein Ewing SW, LaChance HA, Bryan A, Hutchison KE (2009) Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample Addict Biol 14:356-365.
17. First MB, Gibbon M, Spitzer RL, Williams JB (2002) User's Guide for the Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Research Version (SCID-I for DSM-IV-TR, November 2002 Revision). Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
18. Ghoneim MM, Block RI, Ping ST, el-Zahaby HM, Hinrichs JV (1993) The interactions of midazolam and flumazenil on human memory and cognition. Anesthesiology 79:1183-1192.
19. Golden CJ, Freshwater SM (2002) Stroop Color and Word Test: A Manual for Clinical and Experimental Users. Stoelting, Wood Dale, IL.
20. Grobin AC, Matthews DB, Devaud LL, Morrow AL (1998) The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 139:2-19.
21. Guardia J, Trujols J, Burguete T, Luquero E, Cardús M (2007) Impaired response inhibition scale for alcoholism (IRISA): development and psychometric properties of a new scale for abstinence-oriented treatment of alcoholism. Alcohol Clin Exp Res 31:269-275.
22. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E (2005) GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 180:191-205.
23. Heaton RK, Miller SW, Taylor MJ, Grant I (2004) Revised comprehensive norms for an expanded Halstead-Reitan battery (norms, manual and computer program). Psychological Assessment Resources, Odessa, FL.
24. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC (2008) Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci USA 105:3628-3633.
25. Horner MD, Waid LR, Johnson DE, Latham PK, Anton RF (1999) The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav 24:449-453.
26. Kapczinski F, Sherman D, Williams R, Lader M, Curran V (1995) Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients. Psychopharmacology (Berl) 120:220-226.
27. Ke Y, Streeter CC, Nassar LE, Sarid-Segal O, Hennen J, Yurgelun-Todd DA, Awad LA, Rendall MJ, Gruber SA, Nason A, Mudrick MJ, Blank SR, Meyer AA, Knapp C, Ciraula DA, Renshaw PF (2004) Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res 130:283-293.
28. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC (2003) N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 99:79-94.
29. Kumari M, Ticku MK (2000) Regulation of NMDA receptors by ethanol. Prog Drug Res 54:152-189.
30. Lee E, Jang D, Kim J, An SK, Park S, Kim I, Kim S, Yoon K, Namkoong K (2007) Alteration of brain metabolites in young alcoholics without structural changes. Neuroreport 18:1511-1514.
31. Lingford-Hughes AR, Acton PD, Gacinovic S, Suckling J, Busatto GF, Boddington SJ, Bullmore E, Woodruff PW, Costa DC, Pilowsky LS, Ell PJ, Marshall EJ, Kerwin RW (1998) Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy. Br J Psychiatry 173:116-122.
32. Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, Mann K (2009) Impairment of cognitive abilities and decision making after chronic use of alcohol: the impact of multiple detoxifications. Alcohol Alcohol 44:372-381.
33. Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278:144-151.
34. McCrady BS, Smith DE (1986) Implications of cognitive impairment for the treatment of alcoholism. Alcohol Clin Exp Res 10:145-149.
35. McNair DM, Lorr M, Droppleman LF (1971) Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego.
36. Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Nichols ME, Deer EM, Goff WT (1999) Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 40:1279-1285.
37. Mehta AK, Ticku MK (1999) An update on GABAA receptors. Brain Res Brain Res Rev 29:196-217.
38. Miller WR (2004) Combined Behavioral Intervention Manual. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
39. Miller WR, Walters ST, Bennett ME (2001) How effective is alcoholism treatment in the United States? J Stud Alcohol 62:211-220.
40. Mitchell JM, Fields HL, D'Esposito M, Boettiger CA (2005) Impulsive responding in alcoholics. Alcohol Clin Exp Res 29:2158-2169.
41. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987) Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96:122-126.
42. Myrick H, Anton RF (1998) Treatment of alcohol withdrawal. Alcohol Health Res World 22:38-43.
43. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL (2009) A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 33:1582-1588.
44. Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB (1988) Relevance of cue reactivity to understanding alcohol and smoking relapse. J Abnorm Psychol 97:133-152.
45. Noël X, Van der Linden M, Schmidt N, Sferrazza R, Hanak C, Le Bon O, De Mol J, Kornreich C, Pelc I, Verbanck P (2001) Supervisory attentional system in nonamnesic alcoholic men. Arch Gen Psychiatry 58:1152-1158.
46. O'Leary MR, Donovan DM, Chaney EF, Walker RD (1979) Cognitive impairment and treatment outcome with alcoholics: preliminary findings. J Clin Psychiatry 40:397-398.
47. Reitan RM, Wolfson D (1993) The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. 2nd ed. Neuropsychology Press, Tucson, AZ.
48. Robbins TW (2007) Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci 362:917-932.
49. Roberto M, Madamba SG, Moore SD, Tallent MK, Siggins GR (2003) Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. Proc Natl Acad Sci USA 100:2053-2058.
50. Salinsky MC, Binder LM, Oken BS, Storzbach D, Aron CR, Dodrill CB (2002) Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia 43:482-490.
51. Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB (2005) Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64:792-798.
52. Sanna E, Mostallino MC, Busonero F, Talani G, Tranquilli S, Mameli M, Spiga S, Follesa P, Biggio G (2003) Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal. J Neurosci 23:11711-11724.
53. Seifert J, Seeland I, Borsutzky M, Passie T, Rollnik JD, Wiese B, Emrich HM, Schneider U (2003) Effects of acute alcohol withdrawal on memory performance in alcohol-dependent patients: a pilot study. Addict Biol 8:75-80.
54. Skinner HA, Horn JL (1984) Alcohol Dependence Scale: Users Guide. Addiction Research Foundation, Toronto.
55. Smith SS, Gong QH, Hsu FC, Markowitz RS, French-Mullen JM, Li X (1998) GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 392:926-930.
56. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK (1994) Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 12:70-75.
57. Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643-662.
58. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84:1353-1357.
59. Tanaka S (2008) Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation. BMC Neurosci 9:41.
60. Tapert SF, Brown SA (1999) Neuropsychological correlates of adolescent substance abuse: four-year outcomes. J Int Neuropsychol Soc 5:481-493.
61. Tapert SF, Granholm E, Leedy NG, Brown SA (2002) Substance use and withdrawal: neuropsychological functioning over 8years in youth. J Int Neuropsychol Soc 8:873-883.
62. Teichner G, Horner MD, Harvey RT (2001) Neuropsychological predictors of the attainment of treatment objectives in substance abuse patients. Int J Neurosci 106:253-263.
63. Teichner G, Horner MD, Roitzsch JC, Herron J, Thevos A (2002) Substance abuse treatment outcomes for cognitively impaired and intact outpatients. Addict Behav 27:751-763.
64. Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726-732.
65. Urschel HC, Hanselka LL, Gromov I, White L, Baron M (2007) Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc 82:1170-1178.
66. Wicks S, Hammar J, Heilig M, Wisén O (2001) Factors affecting the short-term prognosis of alcohol dependent patients undergoing inpatient detoxification. Subst Abus 22:235-245.
67. Woodward JJ (2000) Ethanol and NMDA receptor signaling. Crit Rev Neurobiol 14:69-89.
68. Zinn S, Stein R, Swartzwelder HS (2004) Executive functioning early in abstinence from alcohol. Alcohol Clin Exp Res 28:1338-1346.